Real-world study assesses antiviral effectiveness and lipid changes in treatment-naïve individuals using a DOR-based regimen, suggesting favorable outcomes.
Key Points
This study aims to evaluate the 48-week antiviral effectiveness and lipid profile changes associated with a DOR-based regimen in HIV treatment-naïve individuals in China.
Conducted a real-world retrospective study involving treatment-naïve individuals initiating DOR/TDF/3TC or other regimens.
Evaluated virologic suppression and CD4 + T-cell counts at week 48.
Compared lipid parameters across different treatment regimens at multiple time points.
96.22% of participants achieved viral suppression with DOR/TDF/3TC and significant increases in CD4 + T-cell counts.
DOR/TDF/3TC showed significant reductions in total cholesterol and triglycerides at weeks 36 and 48 (P < 0.05).
DOR demonstrated lower cholesterol levels compared to EFV and other regimens, highlighting its favorable lipid profile.